CD8+ TILs have been proven to be of favorable prognostic value in several kinds of tumors, including esophageal cancer, colon cancer, intrahepatic cholangiocarcinoma, and prostate cancer (34, 46, 47). This evidence concerns the gene CD8A and prostate cancer.